Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 23;40(6):1559–1573. doi: 10.1161/ATVBAHA.120.314297

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors.

Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — EP4 (prostaglandin E receptor 4) stimulation decreased lysyl oxidase expression via lysosomal degradation. A, Expression of Lox (lysyl oxidase) mRNA level in EP4-Tg vascular smooth muscle cells (VSMCs) stimulated with EP4 agonist or prostaglandin E₂ (PGE₂). n=7 to 8. B and C, Representative blot and relative protein expression of lysyl oxidase for supernatant of EP4-Tg VSMCs stimulated with EP4 agonist±EP4 antagonist or bafilomycin. n=5. D, Images of immunohistochemistry for lysyl oxidase of the abdominal aortas at baseline conditions and after Ang II (angiotensin II) administration (nontransgenic [non-Tg], day28; EP4-Tg, days 7–13). The aorta of EP4-Tg infused with Ang II was ruptured. Scale bars=50 µm. E, Semiquantitative analysis of D. n=5. NS indicates not significant. *P<0.05, **P<0.01.